Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 5
Submit an article Journal homepage
127
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Could siRNA therapeutics change the way we treat dyslipidemia?

Peter E. Pensona Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK;b Liverpool Centre for Cardiovascular Science, Liverpool, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6763-1489View further author information
ORCID Icon &
Alice P. McCloskeya Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK;b Liverpool Centre for Cardiovascular Science, Liverpool, UKView further author information
Pages 315-316 | Received 15 Mar 2024, Accepted 20 May 2024, Published online: 22 May 2024

References

  • Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. [2020 Oct 8];18(1):320. doi: 10.1186/s12916-020-01792-7
  • Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. [2022 Sep 7];43(34):3213–3223. doi: 10.1093/eurheartj/ehac015
  • McCloskey AP, Penson PE, Tse Y, et al. Identifying and addressing pill aversion in adults without physiological-related dysphagia: A narrative review. Br J Clin Pharmacol. 2022 Dec;88(12):5128–5148. doi: 10.1111/bcp.15463
  • Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003 Jun;34(2):154–156. doi: 10.1038/ng1161
  • Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019 Mar 1;115(3):e26–e31. doi: 10.1093/cvr/cvy301
  • Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. [1998 Feb 19];391(6669):806–811. doi: 10.1038/35888
  • Henney NC, Banach M, Penson PE. RNA Silencing in the Management of Dyslipidemias. Curr Atheroscler Rep. [2021 Sep 1];23(11):69. doi: 10.1007/s11883-021-00968-7
  • Dyrbus K, Gasior M, Penson P, et al. Inclisiran-New hope in the management of lipid disorders? J Clin Lipidol. 2020 Jan;14(1):16–27. doi: 10.1016/j.jacl.2019.11.001
  • Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109–119. doi: 10.1016/S2213-8587(22)00353-9
  • Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. [2023 Jan 7];44(2):129–138. doi: 10.1093/eurheartj/ehac594
  • Walker HE, Rizzo M, Fras Z, et al. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. Metabolites. [2021 Dec 9];11(12):857. doi: 10.3390/metabo11120857
  • Naddaf M. First trial of ‘base editing’ in humans lowers cholesterol - but raises safety concerns. Nature. 2023 Nov;623(7988):671–672. doi: 10.1038/d41586-023-03543-z
  • Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. [2022 Nov 28];21(1):263. doi: 10.1186/s12933-022-01684-5
  • Banach M, Cannon CP, Paneni F, et al. Individualized therapy in statin intolerance: the key to success. Eur Heart J. [2023 Feb 14];44(7):544–546. doi: 10.1093/eurheartj/ehac556
  • Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023 Jul;79:2–11. doi: 10.1016/j.pcad.2023.03.001
  • Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017 Feb;26(2):251–259. doi: 10.1080/13543784.2017.1280458
  • Banach M, Penson PE, Vrablik M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021 Apr;166:105499. doi: 10.1016/j.phrs.2021.105499
  • Banach M, Penson PE. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition. Eur J Prev Cardiol. [2022 May 5];29(5):815–816. doi: 10.1093/eurjpc/zwac032

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.